RAPT - RAPT Therapeutics prices equity offering at $30 per share
2025-10-22 02:41:39 ET
More on RAPT Therapeutics
- RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria - Slideshow
- RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript
- RAPT Therapeutics announces proposed public offering
- RAPT Therapeutics jumps on mid-stage data for urticaria candidate
- Seeking Alpha’s Quant Rating on RAPT Therapeutics